What Is the Market Sentiment on ANNX?

Annexon stock is trading -85.71% below its average target price of $15.4 after dropping -57.4% during today's afternoon session. Analysts are giving the small-cap Pharmaceutical company an average rating of buy and target prices ranging from $8.0 to $24.0 per share.

The stock has an average amount of shares sold short at 5.2%, and a short ratio of 6.19. At 2.2%, the company's rate of insider ownership does not indicate that management is deeply invested in the company. Finally, we also note that a significant number of institutional investors are invested in the stock, with 100.7% of Annexon's shares being owned by this investor type.

Institutions Invested in Annexon

Date Reported Holder Percentage Shares Value
2023-03-31 Alerce Investment Management, L.P. 13% 7,056,024 $15,523,253
2023-03-31 Bain Capital Life Sciences Investors, LLC 9% 4,886,616 $10,750,555
2023-03-31 Adage Capital Partners GP L.L.C. 7% 3,549,975 $7,809,945
2023-03-31 Redmile Group, LLC 7% 3,503,190 $7,707,018
2023-03-31 VR Adviser, LLC 6% 3,220,050 $7,084,110
2023-03-31 Federated Hermes, Inc. 6% 3,057,800 $6,727,160
2023-03-31 Citadel Advisors Llc 5% 2,413,117 $5,308,857
2023-03-31 Eventide Asset Management LLC 4% 1,867,250 $4,107,950
2023-03-31 Vanguard Group, Inc. (The) 3% 1,569,971 $3,453,936
2023-03-31 GMT Capital Corp 3% 1,408,697 $3,099,133

Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Annexon.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.